We obtained five hippocampi samples from patients with clinical history of AD and Braak VI tau neuropathology (Table 1) and compared with five Braak I control hippocampi (patients with no dementia and no tau neuropathology) (Table 1) We prepared soluble and insoluble protein fractions (52) and confirmed increased pathologic tau protein in Braak VI compared with Braak I samples (Fig. 6, A and B). This evidence concerns the gene MAPT and Alzheimer disease.